Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5883015 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 11 Pages |
Abstract
Given that evidence suggests achievement of an early response is predictive of improved long-term outcomes, earlier use of these compounds may lead to more rapid, deeper responses corresponding with improvements in patient outcome. Although future studies will benefit from more uniform definitions of end points and methods of analysis, data from published studies of first-line BCR-ABL inhibitor treatment for patients with newly diagnosed CML-CP support the use of dasatinib or nilotinib in place of imatinib.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Elias Jabbour, Jeffrey H. Lipton,